IntelGenx (CVE:IGX) is slated to regain exclusive global rights to develop and sell its Rizaport oral thin-film acute migraine treatment in January, according to a report from BioTuesdays.
The company’s partner, RedHill Biopharma (NSDQ:RDHL), has decided to end its co-development and commercialization relationship with IntelGenx, the news site reported.
Get the full story at our sister site, Drug Delivery Business News.
The post IntelGenx to reclaim global rights to oral thin-film migraine treatment appeared first on MassDevice.
from MassDevice http://ift.tt/2yXUcwD
Cap comentari:
Publica un comentari a l'entrada